

Neurological diseases: Which treatments are appropriate for psoriasis patients with neurological diseases?

Narrative review of the existing literature was conducted.

Results/Answer:

Standard systemic therapy

Ciclosporin

Neurotoxicity is a well-established complication of CsA although it receives surprisingly little attention in literature. A comprehensive review ¹ referencing data from (primarily) the transplant population, estimated that 10 and 28 % of patients receiving calcineurin-inhibitors experience neurotoxic side effects ranging from mild paraesthesia and peripheral neuropathy through to centrally mediated complications such as altered cognition, visual disturbances and seizures. Of these tremor and paraesthesia are the commonest, and in the early trials in psoriasis, affected 40 and 25 % of participants receiving 5mg/kg respectively ². Calcineurin is major component of neural tissue, and plays a key role in the regulation of nerve cell function, and neurotransmission ^{3,4}; toxicity is dose-dependent and largely reversible. Ciclosporin does not readily cross the blood-brain barrier, however, conditions that disrupt the integrity of this, such as neurodegenerative disease, systemic infections, or hypertension, may perhaps also make patients more prone to the neurotoxic effects of CsA ³. Additional factors such as CsA-related hypomagnesaemia ⁵ may also contribute. No studies were identified specifically reporting on outcomes in people with pre-existing neurological disease treated with CsA for psoriasis. Existing guidelines and the SmPC do not stipulate neurological disease to be a contra-indication to treatment.

Fumarates

Dimethyl fumarate (DMF) has more recently been licensed and developed for use in psoriasis and is also a licensed treatment for MS (reviewed in ⁶) at doses of 240 mg BID. Fumarates may be a preferred option for the treatment of psoriasis in people with established MS. There have been a total of nine reports of confirmed progressive multifocal leukoencephalopathy (PML) in patients with psoriasis treated with fumarates; six with Fumaderm[®], two with Psorinovo[®] (a slow release DMF formulation) and one with compounded fumaric acid esters ⁷⁻¹⁵. In all cases, a degree of lymphopenia and/or other contributory factors for PML are thought to have been of direct etiological relevance.



Methotrexate

CNS toxicity is a well-recognized AE of high dose MTX, especially with intra-thecal administration. Low dose oral and s/c MTX have rarely been reported to cause a reversible leukoencephalopathy (see ^{16,17} for recent reports and reviews). The SmPC cites drowsiness, ataxia, blurred vision, transient subtle cognitive dysfunction, mood alteration, and unusual cranial sensations as occasionally reported with low-dose MTX. No studies were identified specifically reporting on outcomes in people with pre-existing neurological disease treated with MTX for psoriasis. Existing guidelines and the SmPC do not stipulate neurological disease to be a contra-indication to treatment.

Biological therapy

TNFi

In vitro, murine and human data suggest that TNF has an important role in the pathogenesis of inflammatory demyelinating disease (reviewed in ¹⁸). However, an early report of increased lesion activity in two MS patients receiving infliximab ¹⁹ as well as the withdrawal of Lenercept (a soluble p55 receptor developed for the treatment of MS) due to increasing severity and duration of symptoms in clinical trial subjects led to heightened awareness of potential risk of TNFi therapy in the context of MS. More recently ²⁰, the single nucleotide polymorphism (SNP) rs1800693 in the TNFRSF1A gene associated with MS but not psoriasis (or other autoimmune conditions) has been shown to direct expression of a novel, soluble form of TNFR1 that can block TNF, hence lending further biological plausibility to a causal relationship between TNF-antagonism and demyelination.

All five TNFi have been associated with aggravation of MS and/or new onset central demyelination, which have been reviewed by Mahil *et al* and Bosch *et al* ^{21,22}. Case reports in more recently licensed TNFi golimumab ^{23,24} and certolizumab ²⁵ have been described. Of 84 cases of central demyelination reported in patients with psoriasis, the majority occurred within the first year of therapy; 33% (25/76) achieved complete recovery after cessation of TNFi +/- adjunctive therapy, 72% (55/76) did not achieve complete clinical recovery after cessation of TNFi therapy. There were fourteen cases of worsening neurological disease despite cessation of TNFi therapy and several reports of new, clinically silent lesions detected on follow-up imaging ^{21,24-35}.

A case control study in rheumatoid arthritis using Canadian administrative claims and an electronic medical records database showed a trend towards an increased rate of demyelination in 891 patients with no risk factors (for demyelination). The authors suggested that TNFi therapy may increase the risk of truly incident demyelinating events by ~30 %, although this result failed to meet statistical significance (adjusted rate ratio 1.31 [95% CI 0.68 to 2.50]) ³⁶. [More recent data from UK and](#)



Scandinavian registries do not show convincing evidence for incident demyelination with TNFi, and if there is an effect, one estimate suggests this is less than 1/1000 patient-years exposure. Thus, to date, it remains the case that trial and pharmacovigilance registry data have not shown any convincing increased risk, although this may relate to a low overall incidence of events and/or exclusion of people at particular risk ³⁷⁻³⁹.

With respect to peripheral disease, all forms of demyelinating neuropathies, including Guillain-Barré syndrome, Miller-Fisher syndrome, multifocal motor neuropathy with conduction blocks, Lewis-Sumner syndrome, and chronic polyradiculoneuritis have been reported in association with TNFi therapy, although the number of case reports in the literature are fewer when compared to central demyelination ^{22,40,41}. One report of five patients providing longer term data (up 3-4 years) indicated that once triggered, chronic demyelinating neuropathy may persist or recur irrespective of whether the TNFi is discontinued ⁴¹. Isolated cases of axonal neuropathy and vasculitis neuropathy are also reported ²². US, UK and German psoriasis guidelines all advise avoidance of or caution with TNFi in people with demyelination and caution in those at risk. Prescribers and patients should also be made aware of symptoms of demyelination when prescribing TNFi to ensure early identification and drug discontinuation.

IL12/23 pathway inhibitors

The IL (interleukin) 12 p40 family of cytokines (IL-12 and IL-23) has been strongly implicated in the pathogenesis of both MS and experimental autoimmune encephalomyelitis (EAE), an animal model that mimics many clinical and histological characteristics of MS. This prompted a phase II study evaluating the role of ustekinumab in patients with relapsing and remitting MS. Patients were randomly assigned 1:1:1:1 to placebo or 27 mg, 90 mg, or 180 mg ustekinumab every four weeks or 90 mg ustekinumab every eight weeks up to week 23. A total of 200 patients received at least one dose of ustekinumab and whilst there was no evidence of benefit, there was no evidence of worsening neurological disease or increase in AEs when compared to placebo. To date, there has been one case report of primary progressive MS in a patient taking ustekinumab for refractory Crohn's disease ⁴² with the first neurological symptoms occurring around one year into therapy. She had received TNFi therapy (infliximab, adalimumab, and certolizumab) prior to ustekinumab. With respect to peripheral demyelinating disease, a single case of Guillain Barré has been reported in a 23-year-old male with refractory Crohn's disease one year after commencing treatment with ustekinumab, having previously been treated with adalimumab ⁴³. A further isolated case of peripheral neuropathy of unspecified etiology after three doses of ustekinumab was reported in an observational, retrospective 5-year



follow-up study of ustekinumab in psoriasis ⁴⁴. Furthermore, the first case of reversible posterior leukoencephalopathy syndrome (RPLS) in a 65-year-old woman who received ustekinumab for over 2.5 years for psoriasis has been reported. She presented with mild hypertension, confusion, headache, nausea, vomiting, multiple seizures. Computed tomographic scans and magnetic resonance images of her head revealed characteristic findings of RPLS. Complete clinical recovery and reversal of the radiologic findings occurred, which is also considered typical of RPLS ⁴⁵. [One case report of an axonal polyneuropathy following guselkumab has been reported which recovered on cessation of drug](#) ⁴⁶. No further data on the newer p19 inhibitors were identified.

IL-17 inhibitors

The IL 17A/F pathway is implicated in both psoriasis and multiple sclerosis, with elevated levels of IL-17A and IL-17F levels detected in both diseases ⁴⁷. Phase II randomised controlled data has shown encouraging results with secukinumab associated with a reduction in both the number of active and new MRI brain lesions in patients relapsing-remitting MS which were reduced by 49% and 67% respectively ⁴⁸; but this is yet to be replicated in further studies. There are five cases in the literature of patients receiving Secukinumab for immune-mediated inflammatory diseases with concomitant MS. 80% (4/5) of patients with MS remained stable with no progression of disease and achieved remission of psoriasis/psoriatic arthritis/ankylosing spondylitis. 20% (1/5) had a relapse of MS and required treatment with rituximab ⁴⁹⁻⁵². There are no reported de novo cases of central demyelination with secukinumab, however longer-term safety data is required. No published data on other IL17 agents (ixekizumab, bimekizumab and brodalumab) were identified.

Summary and synthesis of recommendations

The causal association between TNFi and demyelination remains yet to be proven, although accumulating anecdotal reports, biological plausibility and expert consensus indicate that this class of drugs should be avoided in patients with a clear history of central demyelination. Given evidence for a genetic basis to MS ⁵³, and that asymptomatic first- degree relatives may have morphological evidence of subclinical disease and/or CSF oligoclonal bands (reviewed in ⁵⁴), it would seem prudent to use TNFi with caution in this group too. Dimethyl fumarate is licensed for use in MS, and so may be a preferred first line option, however, surveillance monitoring of peripheral leukocyte counts is strongly recommended in order to minimise the risk of PML. Ustekinumab p19 and anti - IL 17 represent alternative treatment options.



We suggest using fumarates in psoriasis patients with multiple sclerosis.	↑	<p>STRONG CONSENSUS¹</p> <p>100 % Agreement</p> <p>EXPERT CONSENSUS</p>
We recommend against using TNFi therapy in psoriasis patients with a diagnosis of multiple sclerosis or other demyelinating disease.	↓↓	
In psoriasis patients with a first-degree relative with multiple sclerosis or other demyelinating disease, we suggest against the use of TNFi therapy if other suitable treatment options are available.	↓	

¹ due to personal-financial conflict of interest 3 abstentions

References

1. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. *Transplant international : official journal of the European Society for Organ Transplantation* 2000; **13**: 313-26.
2. Ellis CN, Fradin MS, Messana JM *et al.* Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. *The New England journal of medicine* 1991; **324**: 277-84.
3. Tan TC, Robinson PJ. Mechanisms of calcineurin inhibitor-induced neurotoxicity. *Transplantation Reviews* 2006; **20**: 49-60.
4. Arnold R, Pussell BA, Pianta TJ, Lin CS, Kiernan MC, Krishnan AV. Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* 2013; **13**: 2426-32.
5. Thompson CB, Sullivan KM, June CH, Thomas ED. Association between Cyclosporin Neurotoxicity and Hypomagnesemia. *Lancet* 1984; **2**: 1116-20.
6. Venci JV, Gandhi MA. Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis. *The Annals of pharmacotherapy* 2013; **47**: 1697-702.
7. van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. *The New England journal of medicine* 2013; **368**: 1658-9.
8. Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. *The New England journal of medicine* 2013; **368**: 1657-8.
9. Stoppe M, Thoma E, Liebert UG *et al.* Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis. *Journal of neurology* 2014; **261**: 1021-4.
10. Sweetser MT, Dawson KT, Bozic C. Manufacturer's response to case reports of PML. *The New England journal of medicine* 2013; **368**: 1659-61.
11. Buttmann M, Stoll G. Case reports of PML in patients treated for psoriasis. *The New England journal of medicine* 2013; **369**: 1081.
12. Bartsch T, Rempe T, Wrede A *et al.* Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate. *Ann Neurol* 2015; **78**: 501-14.
13. Nieuwkamp DJ, Murk JL, van Oosten BW *et al.* PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. *The New England journal of medicine* 2015; **372**: 1474-6.
14. Dammeier N, Schubert V, Hauser TK, Bornemann A, Bischof F. Case report of a patient with progressive multifocal leukoencephalopathy under treatment with dimethyl fumarate. *BMC Neurol* 2015; **15**: 108.
15. Hoepner R, Faissner S, Klasing A *et al.* Progressive multifocal leukoencephalopathy during fumarate monotherapy of psoriasis. *Neurol Neuroimmunol Neuroinflamm* 2015; **2**: e85.
16. Paudyal B, Viets R, Skliut M. A case of low-dose oral methotrexate-induced reversible neurotoxicity. *AJNR. American journal of neuroradiology* 2010; **31**: E77.
17. Sommer WH, Ganiere V, Gachoud D *et al.* Neurological and pulmonary adverse effects of subcutaneous methotrexate therapy. *Scandinavian journal of rheumatology* 2008; **37**: 306-9.
18. Kaltsonoudis E, Voulgari PV, Konitsiotis S, Drosos AA. Demyelination and other neurological adverse events after anti-TNF therapy. *Autoimmunity reviews* 2014; **13**: 54-8.
19. van Oosten BW, Barkhof F, Truyen L *et al.* Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. *Neurology* 1996; **47**: 1531-4.
20. Gregory AP, Dendrou CA, Attfield KE *et al.* TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. *Nature* 2012; **488**: 508-11.

21. Mahil SK, Andrews TC, Brierley C, Barker JN, Smith CH. Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature. *The Journal of dermatological treatment* 2013; **24**: 38-49.
22. Bosch X, Saiz A, Ramos-Casals M, Group BS. Monoclonal antibody therapy-associated neurological disorders. *Nature reviews. Neurology* 2011; **7**: 165-72.
23. Kay J, Fleischmann R, Keystone E *et al.* Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. *Annals of the rheumatic diseases* 2015; **74**: 538-46.
24. Maillart E, Papeix C, Mellerio C, Bertrand A, Lubetzki C, Louapre C. Extensive and severe CNS demyelination associated with golimumab therapy. *Journal of neurology* 2016; **263**: 1869-71.
25. Barreras P, Mealy MA, Pardo CA. TNF-alpha inhibitor associated myelopathies: A neurological complication in patients with rheumatologic disorders. *J Neurol Sci* 2017; **373**: 303-6.
26. Hare NC, Hunt DP, Venugopal K *et al.* Multiple sclerosis in the context of TNF blockade and inflammatory bowel disease. *Qjm* 2014; **107**: 51-5.
27. Lommers E, Depierreux F, Hansen I, Dive D, Maquet P. NMOSD with anti-MOG antibodies following anti-TNFalpha therapy: A case report. *Mult Scler Relat Disord* 2018; **26**: 37-9.
28. Boggs JME, Barnes L. Demyelination during anti-tumour necrosis factor therapy for psoriasis. *Clinical and experimental dermatology* 2018; **43**: 577-8.
29. Honda Y, Otsuka A, Egawa G *et al.* Multiple neurological abnormalities, including pontine hemorrhage, multiple sclerosis and aseptic meningitis, during anti-TNF-alpha therapy in psoriatic arthritis. *Eur J Dermatol* 2015; **25**: 487-8.
30. Motuzova Y, Di Sapio A, Capobianco M *et al.* Peculiar Cytological Cerebrospinal Fluid Pattern in a Case of Encephalomyelitis During Anti-Tumor Necrosis Factor-alpha Therapy. *Neurol Ther* 2015; **4**: 53-60.
31. Theibich A, Dreyer L, Magyari M, Loch H. Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases. *Clinical rheumatology* 2014; **33**: 719-23.
32. Escalas J, Knopfel N, Martin-Santiago A, Calles C. Acute transverse myelitis during treatment with etanercept for severe plaque psoriasis. *J Am Acad Dermatol* 2014; **70**: e17-8.
33. Sarathchandran P, Alboudi A, AlSuwaidi R, Almadani AA. Iatrogenic transverse myelitis in a patient with rheumatoid arthritis. *BMJ Case Reports* 2019; **12**: e227584.
34. Baumer FM, Ouahed J, Verhave M, Rivkin MJ. Fatal Central Nervous System Disease Following First Infliximab Infusion in a Child With Inflammatory Bowel Disease. *Pediatr Neurol* 2016; **57**: 91-4.
35. Signore SC, Brauns B, Schutze G *et al.* Infliximab-Associated Chronic Inflammatory Central Nervous System Disease and Peroneal Nerve Injury in a Psoriatic Patient Refractory to Treatment: Case Report with 10-Year Follow-Up. *Case Rep Neurol* 2018; **10**: 12-7.
36. Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. *Annals of the rheumatic diseases* 2010; **69**: 1691-3.
37. Kunchok A, Aksamit AJ, Jr., Davis JM, 3rd *et al.* Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events. *JAMA Neurol* 2020; **77**: 937-46.
38. Kopp TI, Delcoigne B, Arkema EV *et al.* Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden. *Annals of the rheumatic diseases* 2020; **79**: 566-72.
39. Taylor TRP, Galloway J, Davies R, Hyrich K, Dobson R. Demyelinating Events Following Initiation of Anti-TNFα Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis. *Neurol Neuroimmunol Neuroinflamm* 2021; **8**.

40. Ramiro S, Gaujoux-Viala C, Nam JL *et al.* Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. *Annals of the rheumatic diseases* 2014; **73**: 529-35.
41. Lozeron P, Denier C, Lacroix C, Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. *Archives of neurology* 2009; **66**: 490-7.
42. Badat Y, Meissner WG, Laharie D. Demyelination in a patient receiving ustekinumab for refractory Crohn's disease. *Journal of Crohn's & colitis* 2014; **8**: 1138-9.
43. Fukushima T, Nakajima K, Nozawa H *et al.* [A case of Crohn's disease complicated by Guillain-Barre syndrome during ustekinumab therapy]. *Nihon Shokakibyo Gakkai Zasshi* 2019; **116**: 324-9.
44. Acer E, Igrek A, Erdogan HK, Saracoglu ZN. Ustekinumab in psoriasis: Five-year real life experience from a single tertiary centre. *Dermatologic therapy* 2020: e13224.
45. Gratton D, Szapary P, Goyal K, Fakharzadeh S, Germain V, Saltiel P. Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature. *Archives of dermatology* 2011; **147**: 1197-202.
46. Hamadah I, Chisti MA. Axonal sensorimotor polyneuropathy after starting guselkumab. *The Journal of dermatological treatment* 2022; **33**: 2371-2.
47. Kolbinger F, Huppertz C, Mir A, Padova FD. IL-17A and Multiple Sclerosis: Signaling Pathways, Producing Cells and Target Cells in the Central Nervous System. *Curr Drug Targets* 2016; **17**: 1882-93.
48. Havrdova E, Belova A, Goloborodko A *et al.* Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. *Journal of neurology* 2016; **263**: 1287-95.
49. Diebold M, Muller S, Derfuss T, Decard BF. A case of concomitant psoriasis and multiple sclerosis: Secukinumab and rituximab exert dichotomous effects in two autoimmune conditions. *Mult Scler Relat Disord* 2019; **31**: 38-40.
50. Assefa GT, Kaneko S, Oguro H, Morita E. Treatment of psoriasis and psoriatic arthritis with secukinumab after unsatisfactory response to ustekinumab in multiple sclerosis patient. *The Journal of dermatology* 2019; **46**: e112-e3.
51. Venturini M, Zanca A, Venturuzzo A *et al.* Secukinumab for patients with plaque psoriasis affected by multiple sclerosis: a mini-review with a representative case report. *Journal of the European Academy of Dermatology and Venereology : JEADV* 2019.
52. Cortese A, Lucchetti R, Altobelli A *et al.* Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases. *Mult Scler Relat Disord* 2019; **35**: 193-5.
53. Ebers GC, Bulman DE, Sadovnick AD *et al.* A population-based study of multiple sclerosis in twins. *The New England journal of medicine* 1986; **315**: 1638-42.
54. Siva A. Asymptomatic MS. *Clinical neurology and neurosurgery* 2013; **115 Suppl 1**: S1-5.